Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News Feature
  • Published:

Cancer drug approvals and setbacks in 2024

Nature Cancer volume 5, pages 1756–1758 (2024)Cite this article

T cell therapies for solid tumors took center stage, while new small-molecule drugs now offer targeted options for hard-to-treat cancers.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Senior, M. Nat. Biotechnol. 42, 1331–1338 (2024).

    Article  CAS  PubMed  Google Scholar 

  2. Mullard, A. Nat. Rev. Drug Discov. https://www.nature.com/articles/d41573-024-00016-4 (15 January 2024).

  3. Harrison, C. Nat. Biotechnol. 42, 1477–1479 (2024).

    Article  CAS  PubMed  Google Scholar 

  4. Healey, N. Nat. Med. https://www.nature.com/articles/d41591-024-00040-2 (30 May 2024)

  5. Choi, B. D. N. Engl. J. Med. 390, 1290–1298 (2024).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Bagley, S. J. et al. Nat. Med. 30, 1320–1329 (2024).

    Article  CAS  PubMed  Google Scholar 

  7. Brown, C. E. et al. Nat. Med. 30, 1001–1012 (2024).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Mullard, A. Nat. Rev. Drug Discov. https://www.nature.com/articles/d41573-024-00150-z (16 September 2024).

  9. Willyard, C. Nature https://www.nature.com/articles/d41586-024-01215-0 (30 April 2024).

  10. Melenhorst, J. J. Nat. Cancer https://doi.org/10.1038/s43018-024-00867-1 (2024).

    Article  PubMed  Google Scholar 

  11. Mullard, A. Nat. Rev. Drug Discov. https://www.nature.com/articles/d41573-024-00088-2 (24 May 2024).

  12. Garber, K. Nat. Rev. Drug Discov. https://www.nature.com/articles/d41573-024-00106-3 (21 June 2024).

  13. Dolgin, E. Cancer Discov. https://doi.org/10.1158/2159-8290.CD-NW2024-0033 (14 May 2024).

  14. Sacher, A. G. et al. Ann. Oncol. 35, S482–S535 (2024).

    Article  Google Scholar 

  15. Guo, R. et al. Ann. Oncol. 35, S482–S535 (2024).

    Article  Google Scholar 

  16. Vieito, M. et al. Ann. Oncol. 35, S482–S535 (2024).

    Article  Google Scholar 

  17. Mullard, A. Nat. Rev. Drug Discov. https://www.nature.com/articles/d41573-024-00170-9 (14 October 2024).

Download references

Author information

Authors and Affiliations

  1. Science journalist, Somerville, MA, USA

    Elie Dolgin

Authors
  1. Elie Dolgin
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Elie Dolgin.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dolgin, E. Cancer drug approvals and setbacks in 2024. Nat Cancer 5, 1756–1758 (2024). https://doi.org/10.1038/s43018-024-00873-3

Download citation

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s43018-024-00873-3

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing